Bcr-Abl

Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.

Bcr-Abl亚型特异性产品:Bcr-Abl Isoform Comparison
共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
Abl protein tyrosine kinase substrate

Abl protein tyrosine kinase substrate 是一种有生物活性的肽,即 Abltide,是 Abl 激酶(Abl 蛋白酪氨酸激酶)的肽底物,而 Abl 激酶是 Abelson 鼠白血病病毒 gag-Abl 融合蛋白的伴侣,该肽用于蛋白质印迹和激酶测定。

1377320-37-0
Substrate
99.70%
Abl protein tyrosine kinase substrate

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础